Toft Group Completes Executive Search for Retrophin, Inc. (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Mr. Scott Generes as Director of Business Development at Retrophin, Inc., in San Diego, CA. Mr. Generes is a senior executive offering 15 years of finance, strategic planning and business development experience within the biotechnology arena. He most recently served with Gradalis, Inc., as their Senior Director, Finance and Strategic Planning. He earned an MBA from UCLA.

About Retrophin, Inc.

Retrophin, Inc. (NASDAQ:RTRX) is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company is focused on advancing the development of its lead pipeline assets: sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease; and RE-024 for pantothenate kinase associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood.

Toft Group Executive Search Expands Team with Michael Young Based in San Diego

April 21, 2017 – San Diego, California: Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, today announced Michael Young has joined as Director based at the company’s headquarters in San Diego, CA. In this role, Mr. Young will focus on placing Director through Executive Level positions for the company’s pharmaceutical, biotech, medical device, technology, and diagnostic clients.

“Mr. Young brings an incredibly dynamic background to Toft Group that includes over 14 years as a Pre-Clinical Research Scientist, and a successful track record of recruiting at leading firms,” commented Robin Toft, President & CEO of Toft Group. “He will be an outstanding addition to our world-class team as we continue to meet a growing demand for highly-skilled leadership in Life Sciences.”

Mr. Young joins Toft Group from National Search Associates (NSA), where he served as Director of Business Development and Sales. Prior to NSA, Michael also served as an Executive Search Consultant with The Newport Group, and was Business Development and Recruiter with Kelly Services, a leading worldwide scientific staffing provider. During his years as a Pre-Clinical Research Scientist, Mr. Young developed/ designed several small molecule and biologics through in vivo and bench assay screens. He began his career as an R&D Scientist with a focus on Immunology and Metabolic disease. Mr. Young spent 12 years with The Genomics Institute of the Novartis Research Foundation (GNF), where many of his projects are now into Clinical Testing within the Novartis pipeline.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. Named a Top 150 Fastest Growing Private Company and a Top 50 Executive Search Firm in Life Sciences, we are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

Toft Group Completes Executive Search for Mesa Biotech, Inc., in San Diego, CA

Executive search firm Toft Group has placed Mr. Steven Sepulveda as the Vice President, Global Business Development & Channel Management for Mesa Biotech, Inc., in San Diego, CA. He brings 15+ years in sales and corporate development, most recently serving in leadership roles for Sekisui Diagnostics and Horiba Medical.

About Mesa Biotech

Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech’s diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa’s technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017.

Toft Group Completes Executive Search for Ascendis Pharma Inc. (NASDAQ: ASND) in Palo Alto, CA

Executive search firm Toft Group has placed Dr. Kamal Bharucha as Director of Clinical Development for Ascendis Pharma in Palo Alto, CA. Dr. Bharucha is trained both as a Scientist and Pediatrician. He spent time in academia before joining the biotechnology community where he most recently served as the Associate Medical Director, Division of Immunology, Infectious Disease and Ophthalmology at Genentech. He earned his MD from Yale University and PhD inn Chemistry from University of California, Berkeley.

About Ascendis Pharma, Inc.

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Toft Group Completes Senior Vice President Search for Oncimmune Holdings plc (AIM: ONCL) in Nottingham, UK

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announced the appointment of Shane Smith as Senior Vice President, Market Access & Reimbursement Oncimmune (USA).

Shane is a commercial leader with more than 15 years’ experience within market access, reimbursement and sales management. He has extensive knowledge of the US market and a proven track record in sales force development, training, government accounts, Managed Care Organisations and laboratory contracting. Shane is highly experienced in molecular diagnostic contracting with national, regional and local health sales plans, as well as reference laboratories and hospital systems of all sizes. In addition, he has successfully managed several high dose immunotherapy centres focused on oncology. His experience also covers recruitment, managing and developing field based talent, conducting coaching, training, and providing directional leadership for both diagnostic and therapeutic products.

Robin Toft, President and CEO of Toft Group said: “We are thrilled to have worked with the senior leadership of Oncimmune Holdings plc, and congratulate Shane on his new role. We have every confidence that he will make an exceptional contribution to the company’s continued success.”

Most recently, Shane was Vice President, Market Access & Reimbursement, Lineagen, Inc. in Salt Lake City, UT where he focused on coverage and value-based reimbursement for Lineagen’s portfolio. He developed and executed Lineagen’s market access and payor strategies for its optimized chromosomal microarray test and its gene sequencing test. Prior to Lineagen, Shane led Market Access, Payer Markets, & Reimbursement for KEW Group where he managed reimbursement contracts and billing policies, working with organisations, business partners, institutions, commercial and government payors to establish coverage and value-based reimbursement for their proprietary next-generation sequencing solid tumor gene test. Earlier in his career, Shane held multiple sales roles with Prometheus Laboratories as well as Novartis Pharmaceuticals Corp.

Geoffrey Hamilton-Fairley, CEO of Oncimmune, said: “I am delighted to welcome Shane to Oncimmune. His appointment means that we have now completed the management team development we outlined at the time of our IPO. With Shane’s wealth of experience adding to our already strong team, I am even more confident we have the necessary sales structure in place to fully exploit our EarlyCDT®-Lung test as well as looking to develop and bring to market other diagnostic tests from across the EarlyCDT® platform.”

Commenting on his appointment, Shane Smith said: “EarlyCDT®-Lung has the potential to detect cancer up to four years earlier than other methods and I hope to use my previous experience in commercialising multiple diagnostic devices to make sure that this test becomes commercially available to as many patients and payors as possible. I am excited about my future at Oncimmune and look forward to sharing in its success.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Dr. David Shack as the Global Director – Diagnostics and Genomics Engineering for Agilent Technologies in Santa Clara, CA. Dr. Shack is a technology and engineering leader offering 20+ years of industry experience. He previously spent the past 11 years with BD Biosciences, most recently with their Genomics division as Senior Director of Engineering. He holds a PhD and Master’s in Mechanical Engineering from Stanford University.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for Specific Technologies in Mountain View, CA

Executive search firm Toft Group has placed Mr. Elias Fayad as Vice President of Software at Specific Technologies in Mountain View, CA. He has been leading software development, data mining and visualization product development projects for almost 20 years. He previously served as the Director of Software Engineering, Instrument Control & Customer Applications for Pacific Biosciences. He holds a Master’s in Biomedical Engineering from The Ohio State University.

About Specific Technologies

Specific’s industry-leading team is developing clinically proven, regulated in vitro diagnostic systems based on a low cost and labor-saving sensor technology that enables rapid detection, Gram status and species identification (ID) of microorganisms directly in the blood culture bottle. The Company’s patented chemical fingerprinting technology combines detection and ID steps into a single, hands-free step, enabling faster time to result, laboratory costs savings and labor saving that speed time from sample-to-answer. Leveraging the same innovative technology, Specific is also developing an antibiotic susceptibility testing (AST) paradigm that would represent a new level of speed, ease of use and affordability in the all-important phenotypic determination of antibiotic susceptibility. These two systems will work in concert to offer a modernized next-generation workflow for the microbiology laboratory.

Toft Group Completes Executive Search for Axovant Sciences (NYSE: AXON) in New York, NY

Executive search firm Toft Group has placed Mr. Timothy King as Senior Director, Market Access for Axovant Sciences in New York, NY. Mr. King’s career spans 20 years of marketing leadership within the pharmaceutical industry. He most recently served as SVP of Strategic Services for Spark Health, LLC. Prior, he spent 13 years with Boehringer Ingelheim, his last role as Director of Biosimilar Marketing supporting market access for their lead immunology candidate. He earned an MBA from the University of Chicago.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Mr. Jeffrey Heimburger as the Senior Director of Marketing, Genomics for Agilent Technologies in Santa Clara, CA. He offers 20 years of marketing leadership experience, most recently serving as a strategy consultant for mobile enterprise start-up ventures and private equity firms.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for EvoFem Biosciences, Inc. in San Diego, CA

Evofem Logo. (PRNewsFoto/Evofem)

Executive search firm Toft Group has placed Dr. Craig Audet as the SVP Regulatory Affairs and Quality Assurance for EvoFem Biosciences, Inc., in San Diego, CA. Dr. Audet is a pharmaceutical industry executive specializing in regulatory affairs, compliance drug and device development and marketing. He most recently served at Arena Pharmaceuticals as Senior Vice President, Operations & Head of Global Regulatory Affairs. He holds a BS in Biology/Pre-med from Boston College and a PhD in Public Health from Walden University.

About EvoFem Biosciences, Inc.

Evofem Biosciences™ is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. Evofem Biosciences develops and markets products that are woman-controlled, non-invasive and rapidly reversible. Women need access to effective products that are well suited to their lifestyle and consistent with their core values.